Introduction
Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are characterized by diarrhea, weight loss, malabsorption of water and nutrients, resulting in debilitating illness 1, 2 .
The dysregulation of water and ion transport occurs as a result of altered epithelial function and is directly involved in the symptoms of IBD. However, the mechanisms underlying this dysfunction are largely unresolved and treatment options are limited 3 .
Increased NO production has been implicated in intestinal inflammation, although the function of NO has been debated as both pro-and anti-inflammatory 4, 5 . The increase in NO occurs through upregulation of NOS2 in epithelial and immune cells, and in neurons and enteric glial cells of the enteric nervous system (ENS) [6] [7] [8] [9] [10] [11] . Enteric glia, long considered to be primarily supportive cells of the ENS, are now known to be actively involved in the maintenance of epithelial barrier function 12 . NOS2-derived NO has been shown to induce epithelial hyporesponsiveness to secretagogues that normally induce apically directed chloride secretion 13, 14 . We have recently described a role for enteric glia in the modulation of nicotinic cholinergic receptor-mediated ion transport 15 . However, whether enteric glia are involved in dysregulating intestinal ion transport during intestinal inflammation is not known.
During intestinal inflammation, enteric glia undergo reactive gliosis 16, 17 , respond to and produce inflammatory mediators 16, 18, 19 and are involved in the breakdown of epithelial barrier function 20, 21 . It has been speculated that enteric glia are involved in the regulation of ion transport during experimental colitis, based on the localization and upregulation of NOS2 in 6 enteric glia during intestinal inflammation 8 . However, a functional role for NOS2 in enteric glia remains to be established.
We tested the hypothesis that enteric glia of the ENS are involved in the dysregulation of ion transport in colitis by directly targeting them using the glial metabolic inhibitor fluoroacetate.
Fluoroacetate has been well characterized as a method of reversibly inhibiting glia metabolic function in the central nervous system, where it is preferentially taken up by astrocytes and their function is reversibly inhibited [22] [23] [24] . Enteric glia have many similarities to astrocytes 25, 26 , and within the ENS, the fluoroacetate metabolite fluorocitrate has been successfully used to demonstrate their role in the regulation of motility 27 . Here we utilize fluoroacetate in conjunction with measurement of intestinal ion transport and NO release from the myenteric plexus to examine the role of enteric glia in the dysregulation of ion transport in the inflamed colon in three mouse models of colitis. We also assessed human colonic biopsies to establish if in the absence of the enteric plexuses we would observe epithelial hyporesponsiveness and if so, if that was reversed by treatment with fluoroacetate. light-dark cycle in a temperature and humidity controlled room. All animals were killed by cervical dislocation under deep isofluorane anesthesia.
Colitis. Colitis was induced using TNBS (0.1mL of 30mg/mL TNBS in 30% ethanol) administered 3 cm intrarectally in animals lightly anesthetized with isofluorane, and DSS (5% w/v) dissolved in drinking water for 5 days followed by 2 days of normal drinking water. TNBS-treated animals were sacrificed 3 days post-treatment and DSS-treated animals were sacrificed 7 days after treatment. The extent of damage induced by intestinal inflammation was assessed in each model using a modified version of an established macroscopic damage score 28, 29 . Briefly, the colonic damage score consisted of the length of damage or length of ulceration (cm), summed with scores for the presence or absence of erythema (0 or 1), diarrhea (0 or 1; defined as loose or watery stool), fecal blood (0 or 1), and adhesions (0, 1 for mild, or 2 for severe). Length of colon (cm) was also recorded.
8 Chronic TNBS colitis. TNBS colitis was induced in mice as described above and animals were subsequently allowed to recover for 3 weeks. Animals had similar initial weight loss as the acute TNBS-treated mice (Table 1) . where the change in I SC (ΔI SC ) is the peak post-stimulus value subtracted from the stable prestimulus baseline. Drugs were added serosally unless otherwise specified and remained in the bath for the duration of the experiment. Electrical field stimulation (EFS; 50V, 10Hz, 3s) was applied in the presence or absence of the following inhibitors: the NOS1 inhibitor S-Methyl-Lthiocitrulline (SMTC; 10µM, Calbiochem, La Jolla, CA), the NOS2 inhibitor N-(3-Aminomethyl) benzylacetamidine (1400W; 10µM, Calbiochem), and the neurotoxin tetrodotoxin (TTX; 500nM, Tocris Bioscience, Ellisville, MO). Additionally, the following agonists were used: substance P Electrochemical Detection of Nitric Oxide. Continuous amperometric monitoring of NO release was conducted on the mucosal surface of full-thickness colon and on myenteric ganglia in myenteric plexus-longitudinal muscle preparations as previously described 15, 30 . Briefly, an NO oxidation current was recorded using a 40µm diameter boron-doped diamond (BDD) microelectrode (described elsewhere 15, 30, 31 ). A stainless steel wire served as the counter electrode and a "no leak" Ag|AgCl electrode (EE009, ESA Biosciences Inc., Sunnyvale, CA) was used as the reference electrode. Amperometric measurements were carried out using a BioStat™ multi-mode potentiostat (ESA Biosciences). The BDD microelectrode was reproducibly positioned over ganglia using a micromanipulator (Model 25033, Fine Scientific Tools, North
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Vancouver, BC). The electrode was held at a detection potential of +1.0 V vs. Ag|AgCl, which was sufficient to oxidize NO at a mass-transfer limited rate. As previously described 15, 30 , tissues were continually perfused with Krebs' buffer at a flow rate of 2 mL/min. For experiments investigating NO release from the mucosa, deoxycholic acid (DCA; Sigma; 1mM) was applied for 30 min and NO release measured at 0 and 30min. The BDD microelectrode was placed 200µm above the mucosal tissue surface for 40s and the currents were recorded at +0.85 V and +1.0 V vs. Ag|AgCl. The difference in the current obtained was due to the oxidation of NO and removed interferences from mucosal melatonin and serotonin release. DCA has previously been demonstrated to cause NO release from NOS2 the intestinal epithelium 32, 33 . For experiments investigating NO release from the myenteric plexus, a local superfusion pipette placed within 100µm of the tissue for 20s containing veratridine (10µM; Sigma) was used to 10 depolarize enteric neurons in the presence or absence of the inhibitors SMTC (10 µM) and 1400W (10µM).
Bacterial Translocation
Examination of bacterial translocation was performed in mice with TNBS colitis or controls, with animals receiving saline or fluoroacetate injections (1mg/kg, IP) every 12h for 3 days. Mice were euthanized by cervical dislocation under deep isofluorane anesthesia and their blood, liver, and spleen tested for translocated bacteria as previously described 13, 34 . Briefly, blood was collected by cardiac puncture and liver and spleen removed using sterile techniques. Statistics. Data are presented as mean ± standard error of the mean (SEM) and were compared using one-way ANOVA followed by post-hoc pair-wise comparisons with Tukey's test, unless otherwise stated. P <.05 was accepted as a level of statistically significant difference.
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Results
The In order to assess the role of enteric glia we used the metabolic inhibitor fluoroacetate [22] [23] [24] .
Under control conditions, fluoroacetate treatment did not alter the ΔI SC in response to EFS in untreated animals (41±8 μA/cm 2 ; n=11; P>.05) or animals treated with a saline-enema (36±6; n=6; P>.05). These data suggest that neither enteric glia nor NO play a regulatory role in electrogenic ion transport under physiological conditions.
Ion transport is inhibited during colitis and is restored by inhibiting NOS2
DSS and TNBS treatment induced weight loss (P<.001 vs. respective controls), extensive inflammation and shortening of the colon (Table 1) . Similarly, Il10 -/-mice had extensive intestinal inflammation with damage scores that were comparable to the chemical models of colitis (Table 1 ).
14 Following the induction of colitis with either TNBS or DSS, the secretory response to EFS was virtually abolished (Figures 1C and 1D) . SMTC had no effect on this response, while 1400W partially restored it, and a combination of SMTC and 1400W were not significantly different to 1400W alone ( Figure 1C ). These data show that in colitis, NO derived from NOS2 is an important inhibitor of electrogenic ion transport.
Inhibiting enteric glial metabolism restores ion transport in colitis
In both TNBS and DSS colitis, fluoroacetate treatment significantly restored the secretory response to EFS and a combination of fluoroacetate and 1400W fully restored the secretory response (Figures 2A and 2B control). These data show that in colitis, enteric glia are involved in the inhibition of electrogenic neurally-mediated chloride secretion. In Il10 -/-mice, the ΔI SC following EFS was greatly reduced compared to SvEv wildtype controls. Fluoroacetate treatment had no effect on the ΔI SC in SvEv mice, but partially restored the secretory response in Il10 -/-mice ( Figure 2C ).
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Enteric glial dysregulation is reversed following recovery from colitis
Animals that were allowed to recover for 3 weeks following the induction of TNBS colitis had similar responses to EFS compared to controls in the presence and absence of fluoroacetate ( Figure 3A ; P>.05). The secretory response to forskolin in TNBS-treated mice was also comparable to controls in the presence and absence of fluoroacetate ( Figure 3B ; P>0.5). Figures 4A and 4B ) or 1400W or a combination of both (not shown) following TNBS or DSS treatment. These data suggested that the fluoroacetate treatment did not alter the epithelial responsiveness to forskolin. 16 We next examined substance P and VIP as they are well-known mediators of epithelial chloride secretion [36] [37] [38] . TTX did not alter the ΔI SC response to VIP in saline enema control ( Figure 4E ) and untreated control conditions ( Figure 4F ). This response was also unaffected by fluoroacetate. In colitis, TTX did not alter the reduced ΔI SC in response to VIP (data not shown). However, following fluoroacetate treatment, TTX now blocked the VIP-induced ΔI SC in both TNBS colitis ( Figure 4E) and DSS colitis ( Figure 4F ). These data suggest that VIP is a mediator of the neurally evoked ion transport response that occurs after fluoroacetate treatment in colitis.
Restoration
Nitric oxide is released from the myenteric plexus following neuronal activation
Having determined that NO from NOS2 and enteric glia is the inhibitory mediator of secretion, we wished to determine whether NO release occurs in the myenteric plexus. Whilst the traditional view of enteric neural regulation of secretion considers that the submucosal plexus is responsible for secretion and the myenteric plexus for motility, our work and that of others suggests that both plexuses together coordinate ion transport 8, 15, [39] [40] [41] . Given the extreme technical difficulty in dissecting the isolated submucosal plexus, we investigated NO signaling within the myenteric plexus. We measured NO release following the application of veratridine, which excites enteric neurons 42 . Under physiological conditions, veratridine caused an increase in NO release that was insensitive to fluoroacetate ( Figure 5A ). This response was largely derived from NOS1 as it was almost completely blocked by treatment with SMTC ( Figure 5B ).
There was a small NOS2 component that was sensitive to 1400W. SMTC and 1400W together completely blocked the NO release ( Figure 5B ). In TNBS and DSS colitis, veratridine caused an increase in NO release that was larger than that observed in controls and was only partially blocked by SMTC, significantly reduced by 1400W, and was completely inhibited by SMTC and 1400W together ( Figures 5C and 5D ).
Inhibiting enteric glial metabolism blocks NO release from the myenteric plexus during intestinal inflammation
We next assessed if inhibiting glial metabolism would decrease the release of NO in colitis. In both TNBS-and DSS-induced colitis, tissues treated with fluoroacetate had reduced NO release from the myenteric plexus following veratridine stimulation compared to untreated TNBS tissue (P<.001). This was completely inhibited by SMTC or in combination with 1400W ( Figures 5E and   5F ), but unchanged by 1400W alone. These data suggest that fluoroacetate inhibits the ability of enteric glia to be stimulated by enteric nerves to produce NO from NOS2.
Fluoroacetate is not a nitric oxide synthase 2 inhibitor
We examined the ability of fluoroacetate to inhibit NO production using DCA, which stimulates NO production from NOS2 in the intestinal mucosa. In the absence of stimulation, the mucosa had a low basal production of NO. DCA treatment increased the production of NO, which was completely blocked by 1400W ( Figure 6 ). The effect of DCA remained unchanged by fluoroacetate treatment (Figure 6 ). These data suggest that fluoroacetate is not a NOS2 inhibitor and reaffirms its preferential inhibitory activity on glia.
Bacterial translocation following intestinal inflammation was decreased by in vivo fluoroacetate treatment
We assessed the effect of fluoroacetate treatment in vivo on damage score and bacterial translocation. In animals without colitis, no damage score was recorded. 
Colonic biopsies from IBD patients have normal ion transport
We found no difference in the ion transport response to EFS between biopsies from the inflamed (17.0 ± 4.5 μA/cm . These results are interesting given our previous findings that nicotinic cholinergic signaling in myenteric ganglia mobilizes NO from NOS2 in enteric glia, which modulates epithelial ion transport under physiological conditions 15 . In contrast to nicotinic cholinergic stimulation, EFS releases many excitatory and inhibitory neurotransmitters from neurons within the ENS, including acetylcholine, substance P and other tachykinins, VIP, adenosine triphosphate, serotonin, and NO 43 . Given that nicotinic cholinergic activation represents only one component of this complex system, it is perhaps not surprising that there are differences when nicotinic stimulation is compared to EFS. 21 During intestinal inflammation, the intestinal epithelium and neural secretomotor pathways are hyporesponsive to secretory stimuli, including the cAMP secretagogue IBMX, acetylcholine, and neural stimulation, persisting even after active inflammation has resolved 8, [44] [45] [46] [47] [48] [49] . The mechanisms mediating epithelial ion transport hyporesponsiveness are not well understood 3 .
The ENS has been implicated, since removal of the submucosal plexus reverses the hyporesponsiveness of the epithelium 3 . Nitric oxide has also been implicated; in a mouse model of colitis, inhibiting NOS2 activation partially restored physiological ion transport following a neural-specific stimulus 48 . The upregulation of NOS2 during intestinal inflammation has been well established [7] [8] [9] . We confirmed that neural stimulation during intestinal inflammation resulted in greater NO release, due to an increase in NOS2 activity in the myenteric plexus.
Additionally, we further investigated the role of NO and confirmed the findings of MacNaughton et al. 48 demonstrating that it was specifically NOS2 inhibition which restored ion transport, while NOS1 inhibition had no effect. Enteric glia are known to be a major source of NOS2 within the ENS, and a role for enteric glia in the regulation of epithelial ion transport during intestinal inflammation has been speculated 8 . Using fluoroacetate to directly investigate the role of enteric glia, we substantially reversed the inhibition of electrogenic ion transport following intestinal inflammation, suggesting that enteric glia play an important role in the inhibition of epithelial ion transport during colitis. Previous work in the ENS has observed that fluorocitrate appears solely to inhibit energy dependent processes in enteric glia 27 . In our study, fluoroacetate prevented NO release specifically from NOS2 without altering NOS1-mediated NO release or inhibiting NOS2 itself, suggesting that fluoroacetate directly targets enteric glial metabolism. 22 An interesting observation was the additive effect of the inhibition of NOS2 and metabolic inhibition of enteric glia in TNBS colitis. In contrast, the electrochemical data suggested that enteric glial NO release from the myenteric plexus is completely inhibited following either the inhibition of NOS2 or enteric glial metabolism. There is a difference between these preparations that helps explain these data. Nitric oxide sensing was done on longitudinal muscle-myenteric plexus preparations, while the ion transport experiments were conducted in full-thickness tissue. Therefore there may be incomplete inhibition in the full-thickness tissue due to penetrance issues. Alternatively, other cellular components or factors regulate the release of NO within the gut wall. The intestinal epithelium itself produces NO during intestinal inflammation 10, 11 . Additionally, infiltrating immune cells could produce NO and modulate the system, although this has not been explored. Finally, other glial populations are present in the gut such as mucosal glia, which help maintain the epithelial barrier and play a role in antigen presentation 12, 16, 20 . However, we do not yet have an adequate way to isolate glial subtypes.
To preclude model-specific effects of our observations, three different models of murine colitis were tested. The chemical models, TNBS and DSS, are acute models of colitis characterized by extensive epithelial damage, although with significant differences in the manifestation of this damage. The Il10 -/-model represents a chronic inflammatory model that develops postnatally and persists over time. All three models have impaired electrogenic ion transport that is reversed by inhibiting glial metabolism. The commonality of enteric glial regulation of intestinal ion transport via NO across multiple models provides good evidence for a common mechanism that may be relevant in IBD. 23 Chloride secretion is regulated at the level of the epithelium primarily by cAMP, but impaired cAMP-mediated secretion during colitis was not altered by fluoroacetate. Similarly, substance P had an impaired secretory response during intestinal inflammation that was unaltered by fluoroacetate. These observations suggest that enteric glia do not directly mediate epithelial responsiveness to secretagogues. However, VIP, another modulator of ion transport, had an impaired secretory response during intestinal inflammation that was partially reversed by fluoroacetate, and was sensitive to TTX, suggesting that VIP may modulate electrogenic ion transport with actions on or through both neurons and enteric glia. VIP has been identified in the majority of neurons in the submucosal plexus of the middle and distal mouse colon 50 and can act as a non-adrenergic non-cholinergic inhibitory neurotransmitter within the ENS, similar to NO 38, 51 . Indeed, VIP colocalizes with NOS1 in the myenteric plexus 37, 52, 53 . Nitric oxide can stimulate VIP release as demonstrated through the application of NO donors, and NOS inhibitors can block VIP release 54, 55 . VIP release could be altered by NOS2 inhibition or the metabolic inhibition of enteric glia during colitis, and therefore when enteric glia are metabolically inhibited, enteric neurons are uninhibited, leading to the restoration of the electrically-evoked secretory response during colitis.
Interestingly, this mechanism of enteric glial dysfunction does not seem to persist following the resolution of intestinal inflammation. In TNBS treated mice, normal secretory function was restored following a three-week post-inflammation period, and was unaltered by fluoroacetate, suggesting that the process in which enteric glia dysregulate ion transport is pathological. 24 We used human biopsy samples in Ussing chambers to describe ion transport in the distal and/or rectosigmoid colon of patients with IBD, comparing inflamed and uninflamed regions from these patients. We found no difference in the ion transport response to EFS between the inhibitor 1400W and fluoroacetate (FA). Note that FA has no effect on DCA-induced NO production (n=4-10/group).
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